Program
feladilimab
Also written as “Feladilimab” and “feladilimab (GSK3359609)”.
Its studies are mostly in Neoplasms · Multiple Myeloma · Carcinoma, Non-Small-Cell Lung · Squamous Cell Carcinoma of Head and Neck · Head and Neck Neoplasms, led by GlaxoSmithKline.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 81 open or running | phase 3since Oct 15, 2019 | Mar 24, 2016 | none ahead |
Also a collaborator on its studies: iteos-belgium-sa, Merck and AstraZeneca.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 24, 2016First study: phase 1 study in NeoplasmsFirst studyNCT02723955 · 829 enrolled · United States, Australia, Canada and more
- Oct 1, 2018Phase 2 study in NeoplasmsNCT03693612 · 26 enrolled · United States, Australia, Canada
- Nov 9, 2018Phase 2 study in NeoplasmsNCT03739710 · 175 enrolled · United States, Canada, France and more
- Oct 15, 2019Phase 3 study in Head and Neck NeoplasmsNCT04128696 · 315 enrolled · United States, Argentina, Australia and more
- Jun 9, 2020Phase 3 study in Head and Neck NeoplasmsNCT04428333 · 117 enrolled · United States, Argentina, Australia and more
- Sep 21, 2022Phase 2 study in NeoplasmsNCT05553808 · 105 enrolled · United States, Canada, France and more
- Jan 22, 2025Phase 2 study in NeoplasmsNCT06790303 · 8 enrolled · United States, Canada, France
- Oct 13, 2025Phase 2 study in Multiple MyelomaNCT07217119 · 25 enrolled · United States, Australia, Canada and more
TargetBeta
“Inducible T-cell costimulator agonist”ChEMBL 37, by rule
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07217119Multiple Myeloma · United States, Australia, Canada and more | 2 | Active, not recruiting | Apr 17, 2025 | 25 |
| NCT06790303Neoplasms · United States, Canada, France | 2 | Terminated | Sep 23, 2021 | 8 |
| NCT05553808Neoplasms · United States, Canada, France and more | 2 | Completed | Sep 23, 2021 | 105 |
| NCT04428333Head and Neck Neoplasms · United States, Argentina, Australia and more | 3 | Terminated | Apr 27, 2021 | 117 |
| NCT04128696Head and Neck Neoplasms · United States, Argentina, Australia and more | 3 | Terminated | Apr 27, 2021 | 315 |
| NCT03739710Neoplasms · United States, Canada, France and more | 2 | Completed | May 2, 2024 | 175 |
| NCT03693612Neoplasms · United States, Australia, Canada | 2 | Completed | Jun 25, 2021 | 26 |
| NCT02723955Neoplasms · United States, Australia, Canada and more | 1 | Completed | Jul 5, 2023 | 829 |
How it is read
Names in the registry
- “Feladilimab”, 5 entries
- “feladilimab”, 2 entries
- “feladilimab (GSK3359609)”, 1 entry
Conditions, from the studies’ own filings
- Neoplasms, 4 studies
- Multiple Myeloma, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
- Squamous Cell Carcinoma of Head and Neck, 1 study
- Head and Neck Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.